SYNCRIP

Across TCGA pan-cancer cohorts, SYNCRIP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYNCRIP data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SYNCRIP mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SYNCRIP expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where SYNCRIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.885	0.499	.006	33	view →
CCRCC	DFS	Tertile	All	0.545	0.825	.004	22	view →
LUAD	OS	Median	III,IV	1.000	0.663	.007	10	view →
PDAC	DFS	Quartile	III,IV	0.223	0.491	.033	3	view →
HNSC	DFS	Quartile	IV	0.451	0.738	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYNCRIP–LSCC (OS)

Open the LSCC breakdown →